Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Honeywell International Inc (HON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Honeywell International Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Honeywell International Inc trades at $225.96 (market cap $71.74B). The key difference: Honeywell International Inc is the larger of the two by market cap, and Honeywell International Inc pays a 4.2% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HON | |
|---|---|---|
Market Cap | $39.89B | $71.74B |
Sector | Health | Industrials |
52-Week High | $491.22 | $248.04 |
52-Week Low | $278.09 | $188.14 |
Enterprise Value | $38.15B | $96.08B |
Dividend Yield | — | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Honeywell International (HON) trades at $226.42, up 1.34% with neutral technical signals. The company maintains strong profitability with 10.89% net margin and 26.41% ROE, though revenue declined slightly to $37.44B in 2025. Recent corporate actions include a 2:1 reverse stock split and dividend payment, while analyst consensus remains bullish with a $402.40 price target. Technical indicators show mixed signals with RSI neutral and ADX suggesting bullish momentum.
HON presents a compelling investment case with strong fundamentals and analyst support, though near-term risks include declining profit margins and increased debt levels. The stock's current valuation at 18.08 P/E appears reasonable given growth prospects in automation and defense sectors, but investors should monitor execution of post-spinoff strategy and macroeconomic headwinds affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
